Small Cap Feast

8th May 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 


Delistings: 







Whats baking in the oven?

Potential Initial Public Offerings:

7th May: Time To ACT plc, an engineering business focused on technology for the energy transition sector, has announced its intention to seek Admission to trading on the Aquis Stock Exchange Growth Market. The Company reports it is revenue generating, profitable in FY23, with £1.9m cash in the bank at 31st March 2024. The Company's application to the AQSE Growth Market is not conditional on it raising funds. However, the Company is seeking to raise up to £1m of new money to de-risk growth and in support of its strategy of coupling organic growth and acquisition.


Reverse Takeovers:


Change of Market:

Dual Listing :


Banquet Buffet

Acuity RM Group 3.8p £4.6m (ACRM.L))

The software Group announces that its subsidiary, Acuity Risk Management Ltd, which supplies the award-winning STREAM software platform for the Governance, Risk and Compliance market, together with associated consultancy services, has signed a new partnership with BSI Group. BSI Digital Risk Advisory is respected for its ability to help organisations navigate the complex landscape of digital risks and develop robust strategies to protect their assets and reputation. This partnership is accompanied by an initial order.

Alliance Pharma 25.4p £137.1m (APH.L)

The healthcare Company announces that Peter Butterfield, Chief Executive Officer, has decided to leave the business in order to pursue other business interests. Following a comprehensive search process, Nick Sedgwick has been appointed as the new CEO, starting 13 May 2024. Peter will remain at Alliance until 30 June 2024 to facilitate a thorough handover. Nick Sedgwick brings thirty years of consumer health experience across European, US and global roles at major multinational companies such as Reckitt, Coty and Nestlé. Most recently Nick was Regional Director for UK and Ireland Consumer Health at Reckitt during which time he increased revenue and improved profitability in the second largest market for the Company.

Andrews Sykes Group 595p £249.1m (ASY.L)

The rental of heating, ventilation, and air conditioning equipment Company announces its preliminary results for the year ended 31 December 2023. Revenue decreased 5% to £78.8m (2022: £83.01m), adjusted EBITDA increased slightly to £30.62m (2022: £30.62m), and the net cash decreased to £24.95m (2022: £27.60m). The Company anticipates continued strength in its core markets despite economic challenges like inflationary pressures and tight labour markets. The Company remains confident in maintaining profitability and expanding into new markets, such as Germany, with the recent incorporation of Klimamieten AS GmbH.

Cornerstone FS 38p £21.8m (CSFS.L)

The foreign exchange and payments solutions Company offering multi-currency accounts to businesses and individuals through its proprietary technology platform announces its audited final results for the year ended 31 December 2023. Revenue increased 100% to £9.6m (2022: £4.8m), adjusted EBITDA increased to £1.7m (2022: loss £0.9m) and the cash balance increased to £2.3m (2022: £0.7m). The strong trading momentum that was experienced during 2023 has been sustained into the current year, which reflects the continued increase in the number of active clients and expansion of the Group's introducer network.

Light Science Technologies Holdings 2.9p £9.7m (LST.L)

The Company comprising three divisions: controlled environment agriculture; contract electronics manufacturing and passive fire protection announces its audited results for the year ended 30 November 2023. Revenue increased 13.8% to £9.3m (2022: £8.2m), loss before tax reduced to £1.14m (2022: £2.72m), and cash and cash equivalents increased to £981k (2022: £590k). Looking forward, the Company is optimistic about the future prospects of Light Science Technologies Holdings.

Lords Group Trading 49.5p £82.0m (LORD.L)

The distributor of building materials in the UK announces that Stuart Kilpatrick will join the Board as CFO and a director of the Company on 4 June 2024. Chris Day, the Group's current CFO and COO, will step down as a statutory director and leave the Group on 17 May 2024 shortly after the publication of the Group's FY23 Results on 15 May 2024. In the short interim period between Chris' departure and Stuart's arrival, the Group is well supported by its strong, well-established finance team who will ensure a smooth transition for the business.

Mobile Tornado Group 2.4p £10.0m (MBT.L)

The push-to-talk over cellular and workforce management solutions provider announces that the Company has secured a contract through its regional partner to supply a range of cutting-edge technologies for a prominent mobile network operator in the Middle East and Africa. Mobile Tornado's technology was selected by the Multi National Operator to deliver lone worker and live video communications services. Mobile Tornado's technology was chosen due to its lower latency, lower data usage and seamless compatibility across connectivity generations from 2G to 5G and WiFi.

Oxford Cannabinoid Technologies Holdings * 0.12p £1.3m (OCTP.L)

The clinical stage biopharmaceutical Company focused on the development and commercialisation of innovative cannabinoid medicines announces that it has applied to the FCA to effect a cancellation of listing of its ordinary shares on the Standard segment of the FCA's Official List and trading on the Main Market for listed securities of the LSE. The Directors have recently completed an internal strategic review exercise which focused on addressing how the Company might best seek to ensure the growth of the Company, with a particular focus on how to attract substantial amounts of new investment to advance their drug development programmes in a timely manner with a low valuation. Given the continued turbulence in the UK public markets, the Directors unanimously concluded that the Cancellation will be in the best interests of the Company, its business and existing shareholders as a whole.

Plant Health Care 4.6p £15.6m (PHC.L)

The provider of peptides for plant protection to global agriculture markets announces an update for the year ended 31 December 2023. Revenue decreased to $11.2m (2022: $11.8m), LBITDA improved 32% to $2.8m (2022: $3.5m). And the cash at 31 December 2023 was $2.1m and increased to $2.3m at 3rd May 2024. New registrations and distribution agreements in 2023 and 2024 point to significant revenue growth in 2024, in line with market forecasts.

XP Factory 14.3p £24.9m (XPF.L)

The leisure businesses operating the Escape Hunt and Boom Battle Bar brands announces an update on trading for the 15-month period to 31 March 2024. Revenue for past 15 months was £57.8m (12 months to Dec 2022: £22.8m), up over 80% on the comparable 15-month period. Furthermore, strong like for like sales growth delivered across both brands in the 13 weeks to 31 March 2024, follows an exceptional year in 2023: Boom: up 11.6% and Escape Hunt: up 11.7%. Overall performance is in line with market expectations for the 15 months to 31 March 2024.

.

8 May 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram